Keymed Biosciences (HKSE:02162) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02162 Keymed Biosciences Inc HKSE:02162
47 GF Score
Price HK$73.55
GF Value HK$151.02
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Keymed Biosciences FFO per Share?

FFO per Share only applies to REITs.

HKSE:02162
47GF Score
Keymed Biosciences Inc HKSE:02162
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Keymed Biosciences (HKSE:02162) Overvalued in 2026?

Based on GuruFocus' analysis, Keymed Biosciences stock appears to be undervalued. The current stock price of HK$73.55 is trading 51.3% below its estimated GF Value™ of HK$151.02. GuruFocus considers Keymed Biosciences to be Possible Value Trap.

Key valuation signals for HKSE:02162:

  • FFO per Share:
  • GF Value™: HK$151.02 vs. price of HK$73.55 (51.3% below fair value)
  • GF Score™: 47/100 with 4 warning signs

No single metric tells the full story. See the HKSE:02162 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Keymed Biosciences Business Description

Other Exchanges 64Z:Germany
Address No. 669 Fenghuang Road, Shuangliu District, Chengdu, Sichuan, CHN, 610219
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China.
47GF Score

Get the complete analysis for HKSE:02162

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$73.55
Price
HK$151.02
GF Value